You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTiagabine
Accession NumberDB00906  (APRD00344)
TypeSmall Molecule
GroupsApproved
DescriptionTiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Structure
Thumb
Synonyms
Gabitril
Tiagabina
Tiagabinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GabitrilTablet, film coated16 mg/1OralCephalon, Inc.1997-11-03Not applicableUs
GabitrilTablet12 mg/1OralSTAT Rx USA LLC1997-11-03Not applicableUs
GabitrilTablet, film coated2 mg/1OralCephalon, Inc.1997-11-03Not applicableUs
GabitrilTablet, film coated4 mg/1OralCarilion Materials Management1997-11-03Not applicableUs
GabitrilTablet4 mg/1OralLake Erie Medical & Surgial Supply DBA Quality Care Products LLC2011-11-15Not applicableUs
GabitrilTablet, film coated4 mg/1OralCephalon, Inc.1997-11-03Not applicableUs
GabitrilTablet, film coated12 mg/1OralCephalon, Inc.1997-11-03Not applicableUs
Tiagabine HydrochlorideTablet, film coated2 mg/1OralTeva Pharmaceuticals Usa, Inc.2016-05-31Not applicableUs
Tiagabine HydrochlorideTablet, film coated2 mg/1OralCima Labs Inc.2012-12-212017-05-31Us
Tiagabine HydrochlorideTablet, film coated4 mg/1OralTeva Pharmaceuticals Usa, Inc.2016-05-31Not applicableUs
Tiagabine HydrochlorideTablet, film coated4 mg/1OralCima Labs Inc.2012-12-212017-08-31Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tiagabine HydrochlorideTablet, film coated2 mg/1OralSun Pharmaceutical Industries Limited2011-11-04Not applicableUs
Tiagabine HydrochlorideTablet, film coated4 mg/1OralSun Pharmaceutical Industries Limited2011-11-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tiagabine hydrochloride
145821-59-6
Thumb
  • InChI Key: YUKARLAABCGMCN-PKLMIRHRSA-N
  • Monoisotopic Mass: 411.1093491
  • Average Mass: 412.0
DBSALT001255
Categories
UNIIZ80I64HMNP
CAS number115103-54-3
WeightAverage: 375.548
Monoisotopic: 375.132670429
Chemical FormulaC20H25NO2S2
InChI KeyPBJUNZJWGZTSKL-MRXNPFEDSA-N
InChI
InChI=1S/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1
IUPAC Name
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid
SMILES
CC1=C(SC=C1)C(=CCCN1CCC[[email protected]](C1)C(O)=O)C1=C(C)C=CS1
Pharmacology
IndicationFor the treatment of partial seizures
Structured Indications
PharmacodynamicsTiagabine is used primarily as an anticonvulsant for the adjunctive treatment of epilepsy. The precise mechanism by which Tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells.
Mechanism of actionThough the exact mechanism by which Tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium- and chloride-dependent GABA transporter 1Proteinyes
inhibitor
HumanP30531 details
Related Articles
AbsorptionTiagabine is nearly completely absorbed (>95%).
Volume of distributionNot Available
Protein binding96%
Metabolism

Tiagabine is likely metabolized primarily by the 3A isoform subfamily of hepatic cytochrome P450.

SubstrateEnzymesProduct
Tiagabine
UnknownDetails
Route of eliminationApproximately 2% of an oral dose of tiagabine is excreted unchanged, with 25% and 63% of the remaining dose excreted into the urine and feces, respectively, primarily as metabolites.
Half life7-9 hours
Clearance
  • 109 mL/min [Healthy subjects]
Toxicitymptoms most often accompanying tiagabine overdose, alone or in combination with other drugs, have included: seizures including status epilepticus in patients with and without underlying seizure disorders, nonconvulsive status epilepticus, coma, ataxia, confusion, somnolence, drowsiness, impaired speech, agitation, lethargy, myoclonus, spike wave stupor, tremors, disorientation, vomiting, hostility, and temporary paralysis. Respiratory depression was seen in a number of patients, including children, in the context of seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Tiagabine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tiagabine.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tiagabine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tiagabine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tiagabine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiagabine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tiagabine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tiagabine.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tiagabine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tiagabine.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Tiagabine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Tiagabine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiagabine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tiagabine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tiagabine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tiagabine.Experimental
AprepitantThe serum concentration of Tiagabine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiagabine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tiagabine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tiagabine.Approved
AtazanavirThe metabolism of Tiagabine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Tiagabine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tiagabine.Vet Approved
AzelastineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tiagabine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tiagabine.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Tiagabine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tiagabine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tiagabine.Approved
BexaroteneThe serum concentration of Tiagabine can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Tiagabine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Tiagabine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Tiagabine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tiagabine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Tiagabine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tiagabine.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tiagabine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tiagabine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tiagabine.Approved, Investigational
BuprenorphineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tiagabine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tiagabine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tiagabine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tiagabine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tiagabine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tiagabine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiagabine.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Tiagabine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tiagabine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tiagabine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiagabine.Approved
CeritinibThe serum concentration of Tiagabine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tiagabine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tiagabine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tiagabine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tiagabine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiagabine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tiagabine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiagabine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tiagabine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tiagabine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Tiagabine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Tiagabine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tiagabine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Tiagabine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tiagabine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tiagabine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tiagabine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tiagabine.Approved, Illicit
ClotrimazoleThe metabolism of Tiagabine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tiagabine.Approved
CobicistatThe metabolism of Tiagabine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tiagabine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tiagabine.Approved, Illicit
ConivaptanThe serum concentration of Tiagabine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Tiagabine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiagabine.Approved
CyclosporineThe metabolism of Tiagabine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tiagabine.Approved
DabrafenibThe serum concentration of Tiagabine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tiagabine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Tiagabine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Tiagabine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Tiagabine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Tiagabine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tiagabine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiagabine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tiagabine.Vet Approved
DexamethasoneThe serum concentration of Tiagabine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tiagabine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tiagabine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tiagabine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tiagabine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tiagabine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tiagabine.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tiagabine.Approved, Illicit
DihydroergotamineThe metabolism of Tiagabine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tiagabine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tiagabine.Experimental, Illicit
DiltiazemThe metabolism of Tiagabine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tiagabine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tiagabine.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tiagabine.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Tiagabine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tiagabine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Illicit
DronedaroneThe metabolism of Tiagabine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tiagabine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tiagabine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tiagabine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tiagabine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Tiagabine can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tiagabine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tiagabine.Approved, Investigational
EnzalutamideThe serum concentration of Tiagabine can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Tiagabine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Tiagabine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Tiagabine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tiagabine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tiagabine.Approved
EthanolTiagabine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tiagabine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tiagabine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tiagabine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tiagabine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tiagabine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tiagabine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tiagabine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tiagabine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tiagabine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiagabine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tiagabine.Illicit, Vet Approved
EtravirineThe serum concentration of Tiagabine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tiagabine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tiagabine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tiagabine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Tiagabine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tiagabine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tiagabine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tiagabine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiagabine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tiagabine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tiagabine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tiagabine.Approved
FluvoxamineThe metabolism of Tiagabine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Tiagabine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Tiagabine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Tiagabine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tiagabine.Approved, Illicit
Fusidic AcidThe serum concentration of Tiagabine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tiagabine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tiagabine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tiagabine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Tiagabine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tiagabine.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tiagabine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiagabine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tiagabine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tiagabine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiagabine.Approved
HydrocodoneTiagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tiagabine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
IdelalisibThe serum concentration of Tiagabine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Iloperidone.Approved
ImatinibThe metabolism of Tiagabine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tiagabine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Tiagabine can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Tiagabine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tiagabine.Approved, Vet Approved
IsradipineThe metabolism of Tiagabine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Tiagabine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Tiagabine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiagabine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiagabine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tiagabine.Approved
KetoconazoleThe metabolism of Tiagabine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiagabine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tiagabine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tiagabine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tiagabine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tiagabine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Tiagabine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tiagabine.Illicit
LopinavirThe metabolism of Tiagabine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tiagabine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tiagabine.Approved
LovastatinThe metabolism of Tiagabine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiagabine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Tiagabine.Investigational
LuliconazoleThe serum concentration of Tiagabine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Tiagabine can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tiagabine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tiagabine.Vet Approved
MefloquineThe therapeutic efficacy of Tiagabine can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tiagabine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tiagabine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiagabine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiagabine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tiagabine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiagabine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tiagabine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tiagabine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiagabine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tiagabine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiagabine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiagabine.Approved
MethotrimeprazineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tiagabine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tiagabine.Approved
MetyrosineTiagabine may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Tiagabine can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiagabine.Approved, Illicit
MifepristoneThe serum concentration of Tiagabine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Tiagabine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Investigational
MirtazapineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Tiagabine can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Tiagabine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tiagabine.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tiagabine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved, Investigational
NafcillinThe serum concentration of Tiagabine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tiagabine.Approved
NefazodoneThe metabolism of Tiagabine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Tiagabine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Tiagabine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Tiagabine can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Tiagabine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tiagabine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tiagabine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tiagabine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tiagabine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tiagabine.Approved, Investigational
OlaparibThe metabolism of Tiagabine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiagabine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tiagabine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tiagabine.Approved, Illicit
OrlistatThe serum concentration of Tiagabine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tiagabine.Investigational
OsimertinibThe serum concentration of Tiagabine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiagabine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tiagabine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tiagabine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tiagabine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tiagabine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Tiagabine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tiagabine.Approved
ParaldehydeTiagabine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tiagabine.Approved, Vet Approved
PentobarbitalThe metabolism of Tiagabine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tiagabine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tiagabine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tiagabine.Approved
PhenobarbitalThe metabolism of Tiagabine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tiagabine.Approved
PhenytoinThe metabolism of Tiagabine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tiagabine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiagabine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Tiagabine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleTiagabine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tiagabine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tiagabine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tiagabine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tiagabine.Approved
PrimidoneThe metabolism of Tiagabine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tiagabine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiagabine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiagabine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tiagabine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tiagabine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tiagabine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tiagabine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tiagabine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiagabine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tiagabine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Tiagabine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiagabine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tiagabine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tiagabine.Approved
RifabutinThe metabolism of Tiagabine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Tiagabine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Tiagabine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiagabine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Tiagabine can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tiagabine.Vet Approved
RopiniroleTiagabine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tiagabine.Approved
RotigotineTiagabine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tiagabine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tiagabine.Experimental
Sage 547The risk or severity of adverse effects can be increased when Tiagabine is combined with Sage 547.Investigational
SaquinavirThe metabolism of Tiagabine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tiagabine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiagabine.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tiagabine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiagabine.Approved, Vet Approved
SildenafilThe metabolism of Tiagabine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Tiagabine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Tiagabine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
St. John's WortThe serum concentration of Tiagabine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Tiagabine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.Approved, Investigational
SulfisoxazoleThe metabolism of Tiagabine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Tiagabine.Approved
SuvorexantTiagabine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Tiagabine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Tiagabine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tiagabine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tiagabine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tiagabine.Investigational
ThalidomideTiagabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiagabine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tiagabine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tiagabine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Tiagabine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tiagabine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tiagabine.Approved
TocilizumabThe serum concentration of Tiagabine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tiagabine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tiagabine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiagabine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tiagabine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tiagabine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tiagabine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tiagabine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiagabine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tiagabine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tiagabine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tiagabine.Approved
Uc1010The risk or severity of adverse effects can be increased when Tiagabine is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tiagabine.Approved, Investigational
VenlafaxineThe metabolism of Tiagabine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Tiagabine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Tiagabine is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Tiagabine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiagabine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tiagabine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiagabine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Tiagabine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tiagabine.Vet Approved
ZolpidemTiagabine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tiagabine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tiagabine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tiagabine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Henning Petersen, Peter Nielsen, Michael Cain, Subhash Patel, “Crystalline Tiagabine monohydrate, its preparation and use.” U.S. Patent US5354760, issued April, 1991.

US5354760
General ReferencesNot Available
External Links
ATC CodesN03AG06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (251 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9603
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5368
P-glycoprotein substrateSubstrate0.6504
P-glycoprotein inhibitor INon-inhibitor0.6879
P-glycoprotein inhibitor IINon-inhibitor0.9609
Renal organic cation transporterInhibitor0.5083
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5299
CYP450 1A2 substrateInhibitor0.5784
CYP450 2C9 inhibitorNon-inhibitor0.6727
CYP450 2D6 inhibitorNon-inhibitor0.812
CYP450 2C19 inhibitorNon-inhibitor0.5865
CYP450 3A4 inhibitorNon-inhibitor0.9568
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7011
Ames testNon AMES toxic0.7455
CarcinogenicityNon-carcinogens0.9505
BiodegradationReady biodegradable0.5139
Rat acute toxicity2.5164 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5333
hERG inhibition (predictor II)Non-inhibitor0.8672
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Cephalon inc
Packagers
Dosage forms
FormRouteStrength
TabletOral12 mg/1
TabletOral4 mg/1
Tablet, film coatedOral12 mg/1
Tablet, film coatedOral16 mg/1
Tablet, film coatedOral2 mg/1
Tablet, film coatedOral4 mg/1
Prices
Unit descriptionCostUnit
Gabitril 16 mg tablet12.53USD tablet
Gabitril 12 mg tablet6.4USD tablet
Gabitril 2 mg tablet4.89USD tablet
Gabitril 4 mg tablet3.9USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5010090 No1994-09-302011-09-30Us
US5866590 No1996-04-292016-04-29Us
US5958951 No1997-06-102017-06-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0211 mg/mLALOGPS
logP4.98ALOGPS
logP2.6ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.14ChemAxon
pKa (Strongest Basic)9.26ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity115.32 m3·mol-1ChemAxon
Polarizability41.7 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as piperidinecarboxylic acids. These are compounds containing a piperidine ring which bears a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPiperidinecarboxylic acids and derivatives
Direct ParentPiperidinecarboxylic acids
Alternative Parents
Substituents
  • Piperidinecarboxylic acid
  • Heteroaromatic compound
  • Thiophene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Neurotransmitter:sodium symporter activity
Specific Function:
Terminates the action of GABA by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A1
Uniprot ID:
P30531
Molecular Weight:
67073.0 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov;66(11):1401-8. [PubMed:16420077 ]
  3. Sheehan DV, Sheehan KH, Raj BA, Janavs J: An open-label study of tiagabine in panic disorder. Psychopharmacol Bull. 2007;40(3):32-40. [PubMed:18007567 ]
  4. Foster AC, Kemp JA: Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. Epub 2005 Dec 22. [PubMed:16377242 ]
  5. Sunol C, Babot Z, Cristofol R, Sonnewald U, Waagepetersen HS, Schousboe A: A possible role of the non-GAT1 GABA transporters in transfer of GABA from GABAergic to glutamatergic neurons in mouse cerebellar neuronal cultures. Neurochem Res. 2010 Sep;35(9):1384-90. doi: 10.1007/s11064-010-0196-1. Epub 2010 May 30. [PubMed:20512624 ]
  6. Henjum S, Hassel B: High-affinity GABA uptake and GABA-metabolizing enzymes in pig forebrain white matter: a quantitative study. Neurochem Int. 2007 Jan;50(2):365-70. Epub 2006 Oct 27. [PubMed:17069932 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 11, 2016 02:39